Longeveron Mesenchymal Stem Cells (LMSCs)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aging Frailty
Conditions
Aging Frailty
Trial Timeline
Jul 6, 2017 → Sep 30, 2021
NCT ID
NCT03169231About Longeveron Mesenchymal Stem Cells (LMSCs)
Longeveron Mesenchymal Stem Cells (LMSCs) is a phase 2 stage product being developed by Longeveron for Aging Frailty. The current trial status is completed. This product is registered under clinical trial identifier NCT03169231. Target conditions include Aging Frailty.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04629105 | Phase 1 | UNKNOWN |
| NCT03169231 | Phase 2 | Completed |
Competing Products
20 competing products in Aging Frailty
Other Products from Longeveron
Allogeneic MSCPhase 2
44
Lomecel-B medicinal signaling cellsPhase 2
44
Peripheral Intravenous (IV) infusion of LMSCsPhase 2
44
Longeveron Mesenchymal Stem CellsPhase 1/2
33
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) + Placebo + Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)Phase 1/2
33